Aripiprazole-induced Obsessive-compulsive Symptoms

Overview

Journal Ind Psychiatry J

Date 2022 Jul 8

PMID 35800864

Authors

Dilshana Nafisa

Anil Kakunje

Affiliations

Soon will be listed here.

Abstract

Aripiprazole is a novel antipsychotic with a unique pharmacological profile as a dopamine partial agonist. It is indicated for treatment of schizophrenia and bipolar disorder. This new antipsychotic has low rate of extrapyramidal side effects, metabolic changes and no significant adverse effect on serum prolactin concentration. In addition,it is not associated with significant weight gain like other atypical antipsychotics. As a reason, when other antipsychotics cause these adverse events, it's not uncommon to switch to Aripiprazole. Obsessive compulsive symptoms have been untoward sequel of a few second-generation antipsychotics. Among the second generation antipsychotics Clozapine, Olanzapine, and Risperidone are the most prominent agents associated with these sequelae, according to case reports. More recently, a handful of case reports indicated development of Obsessive-compulsive symptoms with Aripiprazole. We report a case that exhibited similar unexpected adverse effects after administration of Aripiprazole. Keywords: Aripiprazole, Second generation antipsychotics, Obsessive-compulsive symptoms (OCS).

References

Desarkar P, Das A, Nizamie S . Aripiprazole-induced obsessive-compulsive disorder: a report of 2 cases. J Clin Psychopharmacol. 2007; 27(3):305-6. DOI: 10.1097/01.jcp.0000270091.32286.0a. View

de Bartolomeis A, Tomasetti C, Iasevoli F . Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015; 29(9):773-99. PMC: 4602118. DOI: 10.1007/s40263-015-0278-3. View

Kang S, Noh H, Bae S, Kim Y, Lew H, Lim J . Clozapine generates obsessive compulsive disorder-like behavior in mice. Mol Brain. 2020; 13(1):84. PMC: 7257162. DOI: 10.1186/s13041-020-00621-5. View

Poyurovsky M, Weizman A, Weizman R . Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment. CNS Drugs. 2004; 18(14):989-1010. DOI: 10.2165/00023210-200418140-00004. View

Connor K, Payne V, Gadde K, Zhang W, Davidson J . The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry. 2005; 66(1):49-51. DOI: 10.4088/jcp.v66n0107. View

Keck Jr P, McElroy S . Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert Opin Investig Drugs. 2003; 12(4):655-62. DOI: 10.1517/13543784.12.4.655. View

Tuplin E, Holahan M . Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity. Curr Neuropharmacol. 2017; 15(8):1192-1207. PMC: 5725548. DOI: 10.2174/1570159X15666170413115754. View

Kim D, Barr A, White R, Honer W, Procyshyn R . Clozapine-induced obsessive–compulsive symptoms: mechanisms and treatment. J Psychiatry Neurosci. 2018; 44(1):71-72. PMC: 6306284. DOI: 10.1503/jpn.180087. View

Kodama M, Hamamura T . Aripiprazole-induced behavioural disturbance related to impulse control in a clinical setting. Int J Neuropsychopharmacol. 2009; 13(4):549-51. DOI: 10.1017/S1461145709990976. View

10.

Schlachetzki J, Langosch J . Aripiprazole induced hypersexuality in a 24-year-old female patient with schizoaffective disorder?. J Clin Psychopharmacol. 2008; 28(5):567-8. DOI: 10.1097/JCP.0b013e31818582de. View

11.

Fonseka T, Richter M, Muller D . Second generation antipsychotic-induced obsessive-compulsive symptoms in schizophrenia: a review of the experimental literature. Curr Psychiatry Rep. 2014; 16(11):510. DOI: 10.1007/s11920-014-0510-8. View

12.

Cassano G, Fagiolini A, Lattanzi L, Monteleone P, Niolu C, Sacchetti E . Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy. Clin Drug Investig. 2006; 27(1):1-13. DOI: 10.2165/00044011-200727010-00001. View

13.

SCHOTTE A, Janssen P, Gommeren W, Luyten W, Van Gompel P, Lesage A . Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996; 124(1-2):57-73. DOI: 10.1007/BF02245606. View

14.

Lykouras L, Alevizos B, Michalopoulou P, Rabavilas A . Obsessive-compulsive symptoms induced by atypical antipsychotics. A review of the reported cases. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27(3):333-46. DOI: 10.1016/S0278-5846(03)00039-3. View

15.

Goodman W, McDougle C, Price L, Riddle M, Pauls D, Leckman J . Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder?. J Clin Psychiatry. 1990; 51 Suppl:36-43; discussion 55-8. View

16.

Abi-Dargham A, Laruelle M, Aghajanian G, Charney D, Krystal J . The role of serotonin in the pathophysiology and treatment of schizophrenia. J Neuropsychiatry Clin Neurosci. 1997; 9(1):1-17. DOI: 10.1176/jnp.9.1.1. View

17.

Roxanas M . Pathological gambling and compulsive eating associated with aripiprazole. Aust N Z J Psychiatry. 2010; 44(3):291. DOI: 10.3109/00048670903487282. View

18.

Khullar A, Chue P, Tibbo P . Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS. J Psychiatry Neurosci. 2001; 26(1):55-9. PMC: 1408029. View